Cmt167 Lung Carcinoma
Cmt167 Lung Carcinoma - Related Videos
04:45
3-Dimensional Culture of Lung Carcinoma Cells: A Method To Study Cell-Matrix Interactions
0 Views •
2023
This video describes the technique of 3-D culture of lung carcinoma cells to study the cell-matrix interactions. In the protocol, we will perform the 3D culture of TUM622 lung carcinoma cells to explore its potential of forming organoids in vitro.
07:53
Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression
0 Views •
Cited by 8 •
2020
An in vitro model system was developed to capture tissue architectural changes during lung squamous carcinoma (LUSC) progression in a 3-dimensional (3D) co-culture with cancer-associated fibroblasts (CAFs). This organoid system provides a unique platform to investigate the roles of diverse tumor cell-intrinsic and extrinsic changes that modulate the tumor phenotype.
05:06
A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis
0 Views •
Cited by 2 •
2015
The metastatic spread of cancer is the major cause of cancer-related deaths. We provide an in-depth description of our survival surgery methodology for establishing a “patient-like” orthotopic syngeneic mouse model system for studying the mechanisms of metastasis in solid organ tumors.
04:28
Lung Tumor Cell Recruitment Assay
0 Views •
2019
This manuscript describes a method to quantify tumor cell accumulation in the lungs in an animal model of tumor metastasis.
11:27
Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
0 Views •
Cited by 23 •
2014
Models of spontaneous metastatic renal cell carcinoma (RCC) disease progression can be used for evaluating treatments in a clinically relevant setting. This protocol demonstrates different procedures for orthotopic kidney tumor cell implantation, proper nephrectomy, and finally outlines a necropsy guide for visual and bioluminescent scoring of metastatic burden and localization.
FAQs
The immunocompetent setting allows researchers to examine tumor development while immune cells remain part of the experimental system. This helps connect malignant-cell behavior with immune regulation and communication within the tumor microenvironment. As a result, investigators can evaluate how cancer progression and treatment responses emerge from interactions among tumor, immune, and surrounding stromal cells rather than from malignant cells alone.
Stromal and immune cells contribute to the tumor microenvironment surrounding CMT167-derived tumors and communicate with malignant cells. These interactions provide a way to study how local tissue conditions influence tumor progression, invasion, and immune regulation. Examining this cellular communication can reveal mechanisms that are difficult to interpret when tumor cells are considered separately from their surrounding tissues.
CMT167 studies can examine several connected behaviors, including sustained proliferation, tissue invasion, adaptation, and communication with neighboring cells. Separating these processes helps researchers ask whether tumor expansion reflects continued malignant-cell growth, changes in interaction with surrounding tissues, or both. The model therefore supports mechanistic analysis of how cellular behavior contributes to progression within an organism.
The model links cellular mechanisms to tumor formation and progression in compatible experimental mice. Researchers can therefore relate malignant-cell activity and microenvironmental communication to outcomes observed at the tissue and organism levels. This connection is particularly valuable for studying immune regulation, invasion, metastasis, and treatment responses in a biological context that includes interactions beyond isolated cancer cells.
A typical study introduces CMT167 cells into compatible experimental mice and then examines the resulting tumors. Investigators can assess sustained growth, tissue invasion, communication with stromal and immune cells, and other progression-related outcomes described by the model. The workflow supports comparisons among biological conditions or anticancer treatments while retaining the cellular and organism-level context of tumor development.
Researchers may choose CMT167 when they need to study lung cancer biology in an immunocompetent experimental setting. Its uses include investigating tumor progression, immune regulation, metastasis, and responses to anticancer treatments. The model is especially relevant when the research question depends on interactions between malignant cells and the surrounding tissue rather than on tumor-cell growth alone.
CMT167 research can help investigators examine how experimental anticancer treatments affect tumor progression and responses within an immunocompetent setting. In addition to malignant-cell behavior, studies can consider immune regulation and communication with the tumor microenvironment. These outcomes provide a broader basis for interpreting treatment effects than measurements limited to isolated cancer-cell proliferation.